NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free CELC Stock Alerts $16.94 -0.30 (-1.74%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$16.91▼$17.2350-Day Range$14.35▼$21.6052-Week Range$8.39▼$22.19Volume90,283 shsAverage Volume214,931 shsMarket Capitalization$515.87 millionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Celcuity alerts: Email Address Celcuity MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.2% Upside$29.00 Price TargetShort InterestHealthy6.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$4,952 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.93) to ($3.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.13 out of 5 starsMedical Sector523rd out of 907 stocksMedical Laboratories Industry14th out of 20 stocks 3.5 Analyst's Opinion Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCelcuity has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.11% of the outstanding shares of Celcuity have been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Celcuity has recently decreased by 7.46%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELC. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,952.00 in company stock.Percentage Held by Insiders20.31% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($2.93) to ($3.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -6.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -6.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Celcuity Stock (NASDAQ:CELC)Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Read More CELC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELC Stock News HeadlinesApril 4, 2024 | globenewswire.comCelcuity To Present at Upcoming Needham and Stifel Investor ConferencesApril 3, 2024 | msn.comCelcuity (NASDAQ:CELC): A Biotech with Blockbuster PotentialApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 3, 2024 | finance.yahoo.comCelcuity Gains 12%, Insider Trades Reap BenefitApril 1, 2024 | finance.yahoo.comCelcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | msn.comI Gave Birth At A US Hospital In 2023 — Let's Break Down My $65,000 BillMarch 30, 2024 | msn.comOne dead, another in ICU after drug overdoseMarch 29, 2024 | markets.businessinsider.comGedatolisib’s Promising Clinical Trial Performance and Market Potential Justify Buy RatingApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)March 28, 2024 | finance.yahoo.comQ4 2023 Celcuity Inc Earnings CallMarch 27, 2024 | finance.yahoo.comCelcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key DevelopmentsMarch 27, 2024 | benzinga.comRecap: Celcuity Q4 EarningsMarch 27, 2024 | globenewswire.comCelcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 20, 2024 | globenewswire.comCelcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference CallMarch 15, 2024 | finance.yahoo.comCELC Apr 2024 20.000 callMarch 6, 2024 | globenewswire.comCelcuity to Participate in Leerink Partners Global Biopharma Conference 2024February 28, 2024 | finance.yahoo.comCelcuity to Participate in Cowen’s 44th Annual Health Care ConferenceFebruary 28, 2024 | globenewswire.comCelcuity to Participate in Cowen's 44th Annual Health Care ConferenceFebruary 25, 2024 | msn.comCelcuity (CELC) Price Target Increased by 12.99% to 27.95February 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Celcuity (CELC)February 23, 2024 | msn.comStifel Initiates Coverage of Celcuity (CELC) with Buy RecommendationFebruary 22, 2024 | msn.comStifel starts Celcuity at buy, sees gedatolisib as potential blockbusterFebruary 22, 2024 | finance.yahoo.comCelcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate CancerFebruary 20, 2024 | finanznachrichten.deCelcuity Inc.: Celcuity Appoints Eldon Mayer as Chief Commercial OfficerFebruary 20, 2024 | finance.yahoo.comCelcuity Appoints Eldon Mayer as Chief Commercial OfficerFebruary 20, 2024 | globenewswire.comCelcuity Appoints Eldon Mayer as Chief Commercial OfficerSee More Headlines Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/24/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CELC CUSIPN/A CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$29.00 High Stock Price Target$40.00 Low Stock Price Target$24.00 Potential Upside/Downside+71.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.74% Return on Assets-39.13% Debt Debt-to-Equity Ratio0.26 Current Ratio13.43 Quick Ratio13.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.48 per share Price / Book3.09Miscellaneous Outstanding Shares30,453,000Free Float24,268,000Market Cap$515.87 million OptionableOptionable Beta0.78 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Brian F. Sullivan (Age 62)Co-Founder, Chairman & CEO Comp: $478.12kDr. Lance G. Laing Ph.D. (Age 62)Co-Founder, Chief Science Officer, VP, Secretary & Director Comp: $389.55kMs. Vicky Hahne (Age 58)Chief Financial Officer Comp: $281.59kDr. John R. MacDonald Dabt (Age 69)Ph., Ph.D., Senior Vice President of R&D Ms. Sheri SmithActing Head of Clinical OperationsMr. Igor Gorbatchevsky M.D.Chief Medical OfficerMr. Eldon C. Mayer III (Age 63)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLFulgent GeneticsNASDAQ:FLGTCareDxNASDAQ:CDNASera PrognosticsNASDAQ:SERAViridian TherapeuticsNASDAQ:VRDNView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 1,481,300 shares on 2/26/2024Ownership: 6.121%Richard E BullerSold 350 sharesTotal: $4,952.50 ($14.15/share)PFM Health Sciences LPSold 53,554 shares on 2/15/2024Ownership: 0.649%Commodore Capital LPBought 60,563 shares on 2/14/2024Ownership: 7.251%Pale Fire Capital SEBought 4,000 shares on 2/14/2024Ownership: 0.060%View All Insider TransactionsView All Institutional Transactions CELC Stock Analysis - Frequently Asked Questions Should I buy or sell Celcuity stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CELC shares. View CELC analyst ratings or view top-rated stocks. What is Celcuity's stock price target for 2024? 4 Wall Street research analysts have issued 1 year target prices for Celcuity's shares. Their CELC share price targets range from $24.00 to $40.00. On average, they anticipate the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 71.2% from the stock's current price. View analysts price targets for CELC or view top-rated stocks among Wall Street analysts. How have CELC shares performed in 2024? Celcuity's stock was trading at $14.57 at the start of the year. Since then, CELC shares have increased by 16.3% and is now trading at $16.94. View the best growth stocks for 2024 here. Are investors shorting Celcuity? Celcuity saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,860,000 shares, a drop of 7.5% from the March 15th total of 2,010,000 shares. Based on an average daily volume of 230,800 shares, the short-interest ratio is currently 8.1 days. View Celcuity's Short Interest. When is Celcuity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CELC earnings forecast. How were Celcuity's earnings last quarter? Celcuity Inc. (NASDAQ:CELC) posted its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.06. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID). When did Celcuity IPO? Celcuity (CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
